Supporting clinical research, trials and fellowships

We give grants to New Zealand institutions from the funds we raise. They run clinical research, trials and fellowships with the goal of improving treatment for patients with gut cancers.

Who are our experts and how do we select which trials to fund?

Our Scientific Advisory Committee (SAC) undertakes the critical review of clinical research, trials and fellowships which GCF considers funding. When medical specialists and other health researchers submit funding proposals to GCF, SAC reviews the importance of the question posed in the trial, the design of the trial, and the ability of the trial to yield results that will have a positive impact on cancer treatments. SAC makes recommendations to the GCF Board of Directors, who have the final vote. They approve a sum for the institution running the research, trial or fellowship based on its costs and benefits.

From there, the Principal Investigator (the doctor running the research or trial) or the Fellow seeks approval from the institution’s health research ethics committee. The doctor’s team sets up the infrastructure to run the research or trial and recruit patients who meet the criteria. They monitor the patients and document, analyse and evaluate the results. Many research projects and trials are performed in collaboration with colleagues in Australia or other countries. Finally, the results are published in medical journals to help guide specialists to make the best treatment decisions. Read more information about clinical research and trials.

  • Clinical trials

    Current Trials

    ASCEND - In Development

    ASCEND is a randomised, double blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in patients
    with untreated metastatic pancreatic ductal adenocarcinoma.

    Patients with advanced pancreas cancer have poor survival. Limited penetration of anti-cancer drugs to cancer cells is one of the
    reasons that pancreas cancer is less sensitive to chemotherapy. CEND-1 is a new type of drug that helps small molecules, like chemotherapy drugs, get from the blood stream into cancer cells, without increasing the amount of chemotherapy drug that is taken up by normal cells.

    Even with access to current treatments there is a huge room for improvement given that the average survival for this group of patients is less than 12 months. To improve outcomes for patients with newly diagnosed advanced pancreas cancer, the Australian Gastro-Intestinal Trials Group (AGITG) has developed and sponsored the ASCEND clinical trial.

    The ASCEND clinical trial is investigating whether adding CEND-1 to chemotherapy will improve survival of people with pancreatic cancer by increasing the efficacy of the chemotherapy.

    For participating patients in New Zealand, this trial will have significant dual benefits. Thanks to the support of CEND Therapeutics, every one of the 19 New Zealanders that access this trial will be given the international standard of care treatment gemcitabine and nab-paclitaxel, a treatment option that is not funded in New Zealand. In addition, two-thirds of the patients will receive CEND-1 as part of the investigation into whether this new agent improves the delivery of their chemotherapy treatment.

    The ASCEND trial will begin recruiting New Zealand patients in 2022 and anyone interested in finding out more should discuss it with their specialist.

    MASTERPLAN - In Recruitment

    GCF donors are supporting Dr Iain Ward and the team at the Canterbury Regional Cancer and Haematology service by funding access the MASTERPLAN clinical trial for 2 patients.

    This randomised phase II trial will determine if the addition of SBRT to chemotherapy improves locoregional control for patients with high-risk operable, borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC).

    Surgical removal of tumour is the only potentially curative treatment for pancratic cancer, but tumour recurs at the original site in approximately half of all patients. Any treatments that improve the rate of surgical removal of the tumour are likely to increase overall survival. In patients who cannot be cured, tumour growth in the pancreas often shortens life span and worsens quality of life by invading surrounding tissues. Treatments that control the growth in the pancreas may lengthen life and improve quality of life.

    In patients with tumours that are too advanced for surgery (“locally advanced”) and those for whom surgery has a low chance of removing all tumour (“high risk” and “borderline resectable”), the standard of care is initial chemotherapy followed by reassessment of suitability for surgery.

    SBRT enables the dose of radiotherapy to be increased by more precisely targeting the tumour, while avoiding surrounding tissue. This technique has been shown to improve survival rates and to reduce side effects in the treatment of other cancers, such as lung cancer, in comparison to standard external beam radiotherapy. It is hypothesised that SBRT may increase pancreatic tumour cell death, reduce the likelihood of cancer being left behind after surgery and therefore reduce the likelihood of tumour recurrence at the original site. In patients for who surgery is not possible, SBRT may delay tumour growth in the pancreas, resulting in longer survival and improved quality of life.

    In Follow Up

    TOPGEAR trial

    TOPGEAR is an international, multi-centre, randomised, phase II/phase III clinical trial which is investigating whether the addition of radiation treatment to chemotherapy before a patient’s surgery can improve outcomes such as pathological complete response rates and overall survival.  More than 70 centres across New Zealand, Australia, Canada and Europe are participating in this trial.   All participants received chemotherapy and will be randomly allocated to one of two treatment groups:

    ● preoperative chemotherapy followed by postoperative chemotherapy
    ● OR preoperative chemo-radiation followed by postoperative chemotherapy

    Participants were seen frequently while on treatment, at least 3 weekly while on chemotherapy or chemo-radiation.  Follow up will be every 3 months during year 1 and then every 6 months until 5 years.

    Phase II

    Phase II of the trial enrolled 120 participants before its completion. In early 2015, a planned analysis of data from these 120 participants was performed.  This analysis confirmed that the trial treatment posed no concerns from a safety perspective and the study should continue. The interim phase II feasibility and safety results were published in the Annals of Surgical Oncology, these results showed that pre-operative chemoradiation is safe and feasible and does not adversely affect surgical morbidity. You can view the published article in its entirety by clicking here.

    Phase III

    TOPGEAR has completed recruitment to the phase III component with a total of 574 patients taking part in total.  Auckland City Hospital, Christchurch Hospital, Dunedin Hospital and Waikato Hospital have taken part in and contributed to the TOPGEAR study in the phase II component. Thanks to the Gut Cancer Foundation supporters, Auckland City Hospital continued to recruit patients to the phase III part of the TOPGEAR trial and enrolled another 4 participants onto the study.  This continuation for phase III of the study in Auckland is generously supported by funding from the Gut Cancer Foundation (GCF) and a Research Project Grant from Genesis Oncology Trust, awarded to the Principal Investigator for Auckland City Hospital, Dr Maria Pearse.

    With the trial recruitment now completed, instigators at the Australasian Gastro-Intestinal Trials Group have received additional funding to move into the findings stage. Clinicians will be able to hear an update on TOPGEAR when the trial is presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting in October.

    Click here for a full overview of the study


    GCF has funded Dr Amanda Ashley and her team at Auckland Hospital,three patients to go onto this valuable trial to the value of $23,741.

    ACTICCA-1 is a randomised, controlled, two stage, multicentre Phase III trial comparing gemcitabine+ cisplatin with standard of care (capecitabine) after curative-intent resection of cholangiocarcinoma and muscle-invasive gallbladder carcinoma.

    Cholangiocarcinoma is diagnosed in approximately 80 people every year in New Zealand. In half of these people, curative-intent treatment with surgery is possible. Following this surgery, however, only 20-30% of people survive 5 years. This long-term survival can be increase by giving chemotherapy after the surgery and the current standard is capecitabine. In this trial, patients received either cisplatin and gemcitabine or capecitabine alone following their surgery. The aim is to find out if giving cisplatin and gemcitabine can improve the outcomes for these patients.

    Click here for a full overview of the study

    Closed Trials

    Circulating Tumour DNA as a Biomarker Pancreatic Cancer

    Pancreatic cancer is a devastating cancer with a very poor outlook. The only chance of cure is early diagnosis leading to early surgical resection. Unfortunately this is rare, because by the time of diagnosis, the cancer is usually not resectable. Therefore, we need a tool to diagnose this cancer earlier. Cancers are caused by gene mutations in the DNA inside each cancer cell. We can detect the mutated DNA floating in normal blood. Because the normal DNA in blood has very few mutations, the presence of specific mutated DNA can signal the presence of a cancer.

    This study aims to test whether this mutated DNA can be detected in the blood of patients with pancreas cancer. It may therefore become a useful diagnostic test. This might lead to being able to diagnose the cancer earlier while it is still resectable. This may increase cure rates. The Study: Professor Peter Gibbs is one of three investigators leading this translational clinical study coordinated from the Translational Oncology Group at the Walter and Eliza Hall Institute in Melbourne. This is a collaborative project across several Australian sites. Auckland has been asked to join as the only New Zealand site. Participation in this study will build an excellent collaborative relationship between Auckland and Melbourne. Patients who are undergoing surgery for pancreatic cancer (Stage 1 or 2) will have a blood test before and after surgery. This is the only requirement for patients. They would otherwise have standard workup and clinical follow up. The blood samples will be sent to Melbourne for analysis. DNA and RNA will be extracted from the blood, and searched for mutations. Presence or absence of mutations before and after surgery will then be compared to relapse and survival. Key researcher in Auckland is Dr Ben Lawrence and the Department of Oncology.

    This international trial with 119 participants, concluded that ctDNA has promise for a screening test for pancreas cancer, and for predicting relapse in people with pancreas cancer.  It is now closed and outcomes were presented at ASCO (American Society Conference of Onclologists).

    SCOT (Short Course Oncology Therapy) Trial

    This trial is now closed and results are below.

    Patients who are diagnosed with early bowel cancer may be advised to have chemotherapy treatment for 24 weeks after surgery. This treatment increases their chances of surviving the cancer.  Unfortunately, all chemotherapy treatments have side effects and these side effects often get worse as the treatment goes on.  Previous studies have demonstrated that a shorter course of chemotherapy may be less toxic without being less effective. The aim of the SCOT trial is to definitively answer the question of whether 12 weeks of chemotherapy is as effective in reducing cancer recurrence as the current standard practice of 24 weeks of the same chemotherapy drugs. It is hoped that the 12 week chemotherapy treatment will not only show less side effects than the 24 week treatment, and would be much more convenient, but also would be no less effective. New Zealand patients joined others from around the world, and were randomly assigned to have their treatment for 12 or 24 weeks. Results have been released and show side effects, such as nerve damage, were less for those patients receiving 12 weeks of chemotherapy compared to those receiving 24 weeks. Despite the fact the international study was underpowered, the data suggested that a shorter duration leads to similar survival outcomes with better quality of life and thus might represent a new standard of care.

    A La CaRT (Australasian Laparoscopic Cancer of the Rectum Trial)

    This trial is now closed and results are below.

    GCF was pleased to be able to support New Zealand participation in the Australasian Laparoscopic Cancer of the Rectum Trial (ALaCaRT), which compared laparoscopic assisted (or keyhole surgery) with conventional open surgery for the treatment of rectal cancer. The study enrolled 475 patients from Australia and New Zealand and recently reported the preliminary findings based on an assessment of the adequacy or completeness of removal of the cancer. JAMA October 2015 article click here. Patients were randomly allocated to either laparoscopic or open surgery with the aim of finding out whether or not laparoscopic surgery was as effective as open surgery at removing the cancer. They found that rates of complete tumour removal, as assessed by pathological examination of the removed specimen, were excellent overall, but lower after laparoscopic than open surgery. The study therefore was not able to prove that laparoscopic surgery was as good as open surgery at obtaining complete tumour removal.

    At first impression this may seem like a disappointing result, but there several important messages that we can take from the ALaCaRT trial. The first is that the quality of surgery overall, including the laparoscopic group, was found to be excellent by international standards and this is a common feature of well designed clinical trials; participants tend to receive a very high standard of care. The second message is the importance of clinical trials in determining the role of new treatments, whether these are new drugs or new ways of performing operations. Patients in the ALaCaRT study will continue to be followed up to determine rates of cancer recurrence and long term survival.


    Australasian GI Cancer Trials Group (AGITG) 

    Current trials of interest only open in Australia.

    The MONARCC trial has now opened to recruitment - this trial looks at the best treatments for elderly patients with colorectal cancer. These patients often cannot tolerate standard chemotherapy treatments.

    The SPAR trial investigating rectal cancer has also opened and recruited its first patient. The trial is researching the potential of statin drugs, usually used for cholesterol, for increasing the effectiveness of chemotherapy. The LIBERATE study has opened, which is studying the use of blood tests to detect the presence of tumours earlier than current screening methods.

    For more information on AGITG trials and research go to



  • Clinical research

    Current GCF Supported Research

    Dr Nuala Helsby:

    THYmine2 - An observational study to assess the ability of the thymine loading test to prospectively categorise patients with gastrointestinal or breast cancer who cannot tolerate fluoropyrimidine treatment

    GCF has funded Dr Nuala Helsby and her team at the University of Auckland, a year’s part-time salary for a clinical trial manager to support the following research.

    THYmine2 is an observational study to assess whether the thymine loading test can prospectively categorise patients who cannot tolerate 5-FU treatment (e.g. FOLFOX, CapeOx, FLOX). This treatment is commonly used in GI and breast cancer treatment. Reactions occur in approximately 10% of patients and can result in life-threatening events. Despite extensive research, it is still difficult to determine who is at risk of life-threatening toxicity related to 5-FU. This study aims to examine whether the ratio of thymine to its metabolite in urine can discriminate between patients who tolerate 5-FU and those who experience severe 5-FU related toxicity. If successful then it could be a simple and inexpensive way to identify susceptible patients before they start treatment and allow for dose adjustments or alternative treatment.

    Dr Edmond Ang:

    Does the Gastric Acid Altering Effects of Proton Pump Inhibitors Effect Capecitabine Pharmacokinetics? (APEC Study)

    APEC study team

    Capecitabine is a tablet form of chemotherapy commonly used to treat a variety of cancers affecting the gut and breast. Many patients who are on capecitabine are also on proton pump inhibitors (PPI) (examples include omeprazole/losec and pantoprazole/panzop-relief) for treatment of reflux and indigestion.

    Recently, concerns have been raised that people who use PPIs while on capecitabine have poorer outcomes compared to those who were not on PPIs. One possible explanation for this observation is that reduced acidity in the stomach caused by PPIs may alter how the capecitabine tablet is absorbed into the body. At present, we do not know if this is true and there are no good-quality studies that can clarify this important question.

    APEC a simple study that could test the potential impact of pantoprazole (a common PPI prescribed in New Zealand) on capecitabine absorption among patients undergoing capecitabine treatment for gut and breast cancer. Capecitabine and PPI usage is particularly high in New Zealand, making this study both urgent and relevant.

    This study seeks to answer a concern around day to day oncology practice that may have significant implications for thousands of patients with gut cancers across New Zealand and around the world. In the short term, this study will contribute to a pool of scientific evidence that would either support or refute the concerns raised about the effects of PPI on the pharmacokinetics of capecitabine. This may also provide direction for future research into the question. In the long term, this study, alongside other related studies, will hopefully provide definitive answers on whether to permit or discourage the concurrent use of proton pump inhibitors and capecitabine.

    Click here for a detailed overview of the APEC Study

    GCF is grateful to the Sir Ernest Davis Estate proudly managed by Perpetual Guardian as sole trustee of his charitable trust, for their support of this research.

    Dr Cositha Santhakumar:

    The role of the tumour microenvironment and its implication as a therapeutic target in hepatocellular carcinoma (HCC)

    Every year over 360 New Zealander’s are diagnosed with liver cancer, with significantly higher incidences reported in Maori, Pacifica and Asian populations. Unfortunately, outcomes remain poor with just 15% of liver cancer patients expected to survive beyond 5 years.

    Hepatocellular carcinoma’s (HCC’s) account for 90% of all primary liver cancers. It is believed that the environment in which HCC’s develop has an effect on the biology of the tumour. The study aims to better understand this environment with novel imaging techniques, and determine the role of targeting various components of this environment with immune directed therapies. Dr Santhakumar aims to identify which patients will benefit most from these therapies resulting in tailored patient care and better outcomes.

    Click here for a detailed overview of the research project.

    GCF is grateful to the Sir Ernest Davis Estate proudly managed by Perpetual Guardian as sole trustee of his charitable trust, for their support of this research.



    Dr Janet Rhodes - Recipient of the Gut Cancer Foundation GI Fellowship:

    Refining multiplex immunohistochemistry to quantify in situ immune infiltrate: improving survival of colorectal cancer patients

    Traditionally, diagnosing a stage 2 and 3 colorectal cancer has not provided an accurate prognosis and an appropriate level of treatment. As such, researchers have sought to develop a tool that more accurately predicts prognosis for this group of patients.

    Immunoscoring is a system designed to measure the extent to which a few parts of the patient’s immune system has affected (infiltrated) colorectal cancer tumours. It identifies two cell markers which could play a role as more accurate predictors of a patient’s  susceptibility to tumour recurrence and therefore a more accurate predictor of their potential outcome.

    Early evidence suggested confirms that immunoscoring stage II and III colorectal cancer patients could be used to provide more accurate prognosis and therefore give patients more tailored treatments and hopefully improve survival rates.

    Further research in NZ has taken these findings and confirmed in a very small cohort that immunoscoring was able to predict whether or not tumours would recur in patients with stage II colorectal cancer – confirming that proactive use of immunoscoring has the potential for far more accurate prognosis and tailored treatment plans.

    But, this research was only conducted on a small number of tumour samples. Significant research was required to establish whether immunoscoring is an effective prognosis tool using a much larger selection of tumour samples. This work needs to be established before immunoscoring can be used as standard practice.

    However, the existing techniques for immunoscoring were extremely expensive, and therefore inaccessible to researchers and clinicians in NZ. Other tentative methods were very labour intensive and not easily translated into practical diagnostic settings. As such, new more efficient immunoscoring techniques needed to be developed to make this additional research possible and help it translate into a clinical setting if the research provides positive outcomes.

    To address these issues, Dr Rhodes designed her PhD to:

    • establish the techniques necessary to enable immunoscoring of a much larger set of patients and ensure the technique is translatable into a diagnostic setting
    • establish whether this refined immunoscore technique does in fact add value to determining the prognosis of  NZ colorectal cancer patients
    • Identify additional characteristics of the immune response (cell markers) to the tumour that could add to the efficacy of immunoscore as a diagnostic tool


    To date,  Dr Rhodes' research has successfully managed to:

    • develop a new, quicker, more efficient, cheaper immunoscoring technique that allows her to test and validate the technique against tumour specimens from over 500 NZ colorectal cancer patients
    • Identify additional immune responses and cell markers that could help improve the accuracy of the technique
    • Develop a system that, with some refinement, may have an immediate impact on the treatment of New Zealanders with stage II and III colorectal cancer by providing a more accurate prognosis and allowing for a more personalised treatment plan
    • Developed a system that could have immediate benefits to Kiwis whilst simultaneously contributing to a much wider global effort to improve the accuracy of  the Immunoscore as a prognostic tool

    GCF is grateful to the Hugh Green Foundation for their support of this research.


    Past GCF Supported Research

    Professor Peter Shepherd and Dr Khanh Tran:

    A pre-clinical study to investigate the potential for a novel drug combination for treating colorectal cancer

    Research Overview

    Professor Peter Shepherd and his team at the University of Auckland, have been awarded $50,000 for a second year to study a form of colorectal cancer which is difficult to treat normally. A drug combination used to treat melonoma will be trialed in the laboratory as a pre-clinical experiment to determine if there is any tumour response using the drugs vemurafenib and axitinib.  This funding is thanks to the Ted and Mollie Carr Fund and Estate of Ernest Davis through Perpetual Guardian.


    The results of this vital research indicate that the combination of drugs trialled in laboratory conditions are more successful than existing treatments, in treating the 10% of colon cancers that are driven by mutations in the BRAF gene.

    Professor Shepherd said “These result support previous work funded by the Gut Cancer Foundation and provides solid evidence to support human clinical trials of these two drugs together to be used, specifically in patients whose tumours contain a BRAF mutation. This represents about 10% of all colorectal cancers and is important as people with such tumours have worse clinical outcomes and hence the need for improved treatment.

    Click here for a detailed overview of the research project and its findings.

    GCF is grateful to the Sir Ernest Davis Estate proudly managed by Perpetual Guardian as sole trustee of his charitable trust, for their support of this research.


    Dr Roslyn Kemp, Department of Microbiology and Immunology, University of Otago.

    "In colorectal cancer, a strong immune response within the tumour is associated with a good outcome for patients. We will validate this finding, for the first time, in New Zealand patients. We will also use a new technology to characterize these immune cells to determine their mechanisms of action" GCF has awarded Dr Kemp and her team $50,000 for this valuable Clinical Research. Funding for this research has been completed and we await outcomes as the research is completed and published.




    Dr Rachel Purcell, University of Otago.

    "New Zealand has one of the highest rates of colorectal cancer (CRC) in the world. We aim to classify CRC using gene-expression profiles in order to improve treatment strategies and outcomes. We will also study CRC microbiomes to determine the role of bacteria in the development of CRC subtypes" GCF has awarded Dr Purcell and her team $50,000 for this valuable Clinical Research with the support of the Hugh Green Foundation. Funding for this research has been completed.

    Outcomes include the following:

    CMS1 is associated with right-sided tumours in females, node negative and poorly differentiated tumours. CMS2 tumours were predominantly left-sided and in male patients. CMS4 were more often found in younger patients, those with rectal tumours and higher stage. Interestingly, we did not find any prognostic benefit of stratifying tumours using CMS, in contrast to the published literature on CMS. In our treatment-naïve cohort, TNM remains the most useful method of tumour stratification. A manuscript has been prepared detailing these findings and submitted for publication.




  • Clinical trial applications

    Clinical trials can be accepted all year round. Email forms below to

  • Clinical research and fellowships available

    Subject title: GCF: Call for Applications – Part time 0.3-0.5 FTE GI Cancer Clinical Research Fellowship or Clinical Research Project in the Auckland region only

    The Gut Cancer Foundation is calling for applications for:

    Part time GI Cancer Clinical Fellowship or Clinical Research


    The Gut Cancer Foundation offers one part time 0.3-0.5 FTE GI Cancer Clinical Research Fellowship award each year. The Fellowship is for the support of outstanding graduates working in the Auckland region from all relevant health professions, who are able to combine their clinical work with research to improve the quality of life and potential survival for people living with a GI cancer.

    The Fellowship is tenable for a period of one year. Applications are open to appropriately qualified, Auckland based, individuals with New Zealand residency, permanent residency or citizenship, who hold a relevant degree or are in the process of completing their training.

    The GI Cancer Clinical Fellowship would be available in (but not limited to) the specialty areas of cancer surgery, radiation oncology, medical oncology, palliative care, cancer genetics, radiology, anatomical pathology, nutrition, psychiatry or public health.

    The salary will be the equivalent to the appropriate level of remuneration of the applicant’s current employment. Please provide evidence of your current salary per annum. The Foundation will provide a contribution towards working expenses of $5,000 per annum. The Foundation has a total of $45,000 per annum for remuneration of salary costs only.

    Clinical Research Project

    This application can also be in the form of a GI Cancer Clinical Research project to the value of $50,000 (GST excl) annually in the Auckland region. Preference is for a new project though applications for funding of existing projects will be considered on their merits. The criteria for applicants are the same as for the Fellowship including the requirement that the research is conducted in  the Auckland region.

    General information

    All recipients would be expected and required to acknowledge funding support from GCF and the Ted and Mollie Carr fund through Perpetual Guardian, in oral or written reports about their work.  The successful applicant must be prepared to have a profile posted on GCF’s website and promoted through GCF’s marketing material. Six monthly progress reports are required using the provided accountability template.

    Applications should be made on the Research Proposal form attached and needs to include the proposed research, and also information about the applicant, description of how his/her time will be allocated, and demonstration of value to their career.

    Applications forms are below and must be received by GCF NZ by email to by 5 pm, 1st March 2020.  Please note that your host institution may have an earlier closing date and GCF strongly encourages you to adhere to the internal deadline.  Please also ensure that you also fulfill any institutional requirements for submission.

    The decision will be made by GCF’s Scientific Advisory Committee and ratified by the Gut Cancer Foundation board of directors. Applicants will be notified by of the final decision by 1st April 2020.